Browse the corpus

Blood glucose monitoring (BGM) is a cornerstone of diabetes management, enabling detection of glycemic patterns in response to diet, physical activity, medications, and underlying pathological processes. Accurate and timely glucose assessment is essential, as both hyperglycemia and hypoglycemia can lead to acute, life-threatening emergencies and long-term microvascular and macrovascular complications.[1][2] According to the International Diabetes Federation, an estimated 589 million adults aged 20 to 79 years were living with diabetes in 2024, a figure projected to rise to 852.5 million by 2050, underscoring the growing clinical importance of reliable glucose monitoring across all healthcare settings. [International Diabetes Federation. IDF Diabetes Atlas, 11th ed. Brussels: International Diabetes Federation; 2025] Glycemic status can be assessed through multiple modalities. Capillary blood glucose (CBG) testing using point-of-care glucometers remains widely used for self-monitoring of blood glucose outside clinical facilities, while laboratory-based venous plasma glucose measurement and hemoglobin A1c (HbA1c) testing serve diagnostic and long-term glycemic evaluation purposes. Continuous glucose monitoring (CGM) systems, which measure interstitial fluid glucose and provide real-time trend data, have become increasingly integral to diabetes care. The 2026 American Diabetes Association (ADA) Standards of Care now recommend CGM use at the onset of diabetes and at any time thereafter for adults with diabetes on insulin therapy, on noninsulin therapies that can cause hypoglycemia, and on any diabetes treatment in which CGM aids management, substantially expanding the role of continuous monitoring.[3][4] Regardless of the monitoring method employed, the accuracy and reliability of glucose measurements depend on adherence to established quality control practices, including internal quality control (IQC), external quality assessment (EQA), and laboratory safety protocols. Effective BGM extends beyond generating numerical data; it requires interpretation within the context of each patient’s clinical presentation and integration into individualized treatment plans by a coordinated interprofessional healthcare team.[1][2]

Dietary carbohydrates are broken down in the gastrointestinal tract into simpler sugars, primarily glucose, which is absorbed in the small intestine and transported via the bloodstream to cells throughout the body, including the liver. In response to rising postprandial blood glucose levels, pancreatic beta-cells secrete insulin, which facilitates cellular glucose uptake in insulin-sensitive tissues (skeletal muscle, liver, and adipose tissue), inhibits hepatic gluconeogenesis, and promotes glucose storage as glycogen (glycogenesis) and, to a lesser extent, as fat through de novo lipogenesis.[1] The body maintains blood glucose homeostasis within a narrow range of approximately 3.9 to 5.5 mmol/L (70 to 99 mg/dL) through the opposing actions of insulin and counter-regulatory hormones. When blood glucose falls, pancreatic alpha-cells secrete glucagon, which stimulates hepatic glycogenolysis and gluconeogenesis to raise blood glucose levels. Other counter-regulatory hormones, including cortisol, epinephrine, and growth hormone, further support glucose mobilization during fasting, stress, and the early-morning hours (the dawn phenomenon).[5] In addition to direct glucose sensing by beta-cells, postprandial insulin secretion is augmented by the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), which are released from enteroendocrine cells in the gut in response to nutrient ingestion. Beyond their insulinotropic effect, incretins suppress glucagon secretion, delay gastric emptying, and promote satiety, thereby contributing to overall glucose regulation.[6] This tightly regulated balance between insulin-mediated glucose disposal, incretin-augmented insulin release, and counter-regulatory glucose production is central to normal glycemic control.

The body maintains blood glucose homeostasis within a narrow range of approximately 3.9 to 5.5 mmol/L (70 to 99 mg/dL) through the opposing actions of insulin and counter-regulatory hormones. When blood glucose falls, pancreatic alpha-cells secrete glucagon, which stimulates hepatic glycogenolysis and gluconeogenesis to raise blood glucose levels. Other counter-regulatory hormones, including cortisol, epinephrine, and growth hormone, further support glucose mobilization during fasting, stress, and the early-morning hours (the dawn phenomenon).[5] In addition to direct glucose sensing by beta-cells, postprandial insulin secretion is augmented by the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), which are released from enteroendocrine cells in the gut in response to nutrient ingestion. Beyond their insulinotropic effect, incretins suppress glucagon secretion, delay gastric emptying, and promote satiety, thereby contributing to overall glucose regulation.[6] This tightly regulated balance between insulin-mediated glucose disposal, incretin-augmented insulin release, and counter-regulatory glucose production is central to normal glycemic control. In diabetes mellitus, this homeostatic mechanism is disrupted. In type 1 diabetes, autoimmune destruction of pancreatic beta-cells results in absolute insulin deficiency. In type 2 diabetes, a combination of insulin resistance in peripheral tissues and progressive beta-cell dysfunction leads to relative insulin deficiency and impaired glucose utilization.[1] A diminished incretin effect, in which the glucose-lowering response to GLP-1 and GIP is attenuated, further contributes to postprandial hyperglycemia in type 2 diabetes and has become a key therapeutic target for glucagon-like peptide-1 receptor agonist (GLP-1 RA) and dual GLP-1/GIP receptor agonist therapies.[6] In both forms of diabetes, the resulting imbalance between insulin action and counterregulatory hormone activity leads to hyperglycemia. Patients with impaired glucose homeostasis and persistently elevated fasting blood glucose are at high risk of developing overt diabetes mellitus and its associated microvascular and macrovascular complications.[1][7]

In diabetes mellitus, this homeostatic mechanism is disrupted. In type 1 diabetes, autoimmune destruction of pancreatic beta-cells results in absolute insulin deficiency. In type 2 diabetes, a combination of insulin resistance in peripheral tissues and progressive beta-cell dysfunction leads to relative insulin deficiency and impaired glucose utilization.[1] A diminished incretin effect, in which the glucose-lowering response to GLP-1 and GIP is attenuated, further contributes to postprandial hyperglycemia in type 2 diabetes and has become a key therapeutic target for glucagon-like peptide-1 receptor agonist (GLP-1 RA) and dual GLP-1/GIP receptor agonist therapies.[6] In both forms of diabetes, the resulting imbalance between insulin action and counterregulatory hormone activity leads to hyperglycemia. Patients with impaired glucose homeostasis and persistently elevated fasting blood glucose are at high risk of developing overt diabetes mellitus and its associated microvascular and macrovascular complications.[1][7] Certain organs, notably the brain, kidneys, liver, and erythrocytes, do not require insulin for glucose uptake and are therefore particularly vulnerable to fluctuations in blood glucose levels. The brain is critically dependent on a continuous glucose supply; acute, chronic, or recurrent hypoglycemia can result in significant neurological morbidity, including cognitive impairment, seizures, and loss of consciousness.[8] Conversely, sustained hyperglycemia contributes to oxidative stress and the formation of advanced glycation end products, driving the microvascular and macrovascular complications of diabetes.[7][9] Glucose is present in both the blood and the interstitial fluid; however, interstitial glucose levels may lag behind blood glucose, particularly during periods of rapid glycemic change. This physiological relationship is directly relevant to clinical practice, as CBG testing measures plasma glucose, while CGM systems measure interstitial fluid glucose. Understanding these compartmental differences and the underlying pathophysiology of glucose regulation is essential for accurate interpretation of monitoring data and appropriate clinical decision-making.[3][Sensors and Actuators Reports. A systematic review of continuous glucose monitoring sensors: principles, core technologies and performance evaluation. Dec 2025]

Managing diabetes mellitus to improve patient outcomes requires a coordinated, interprofessional approach that integrates clinical expertise, patient engagement, and evidence-based practice. Current evidence supports the use of structured care models, such as the Chronic Care Model (CCM), which emphasizes proactive, team-based care; self-management support; decision support at the point of care; clinical information systems, including patient registries; community resources; and a quality-oriented health system culture. Randomized controlled trials of CCM-aligned programs have demonstrated significant reductions in HbA1C, with greater improvements observed in interventions incorporating 4 or more CCM elements, as well as improvements in blood pressure and processes of diabetes care. Team-based care interventions specifically have been associated with a mean HbA1C reduction of 0.5%, along with significant improvements in systolic and diastolic blood pressure and low-density lipoprotein cholesterol. These findings underscore that effective glycemic management extends beyond numerical values and requires sound clinical judgment, ethical decision-making, and individualized, patient-centered strategies that address the physiological, psychosocial, and socioeconomic dimensions of diabetes.[30][31] A systematic approach to managing altered blood glucose levels depends on active collaboration across an interprofessional team that includes the patient as an informed partner. Individuals with diabetes should receive care from a coordinated team that may include, but is not limited to, diabetes care and education specialists; primary care and subspecialty clinicians, including endocrinologists; nurses, including registered nurses and nurse practitioners; registered dietitian nutritionists; clinical pharmacists; exercise specialists; podiatrists; dentists; behavioral health professionals; laboratory professionals; community health workers; and care coordinators or navigators.

A systematic approach to managing altered blood glucose levels depends on active collaboration across an interprofessional team that includes the patient as an informed partner. Individuals with diabetes should receive care from a coordinated team that may include, but is not limited to, diabetes care and education specialists; primary care and subspecialty clinicians, including endocrinologists; nurses, including registered nurses and nurse practitioners; registered dietitian nutritionists; clinical pharmacists; exercise specialists; podiatrists; dentists; behavioral health professionals; laboratory professionals; community health workers; and care coordinators or navigators. Each discipline contributes distinct expertise to BGM and diabetes management. Physicians and advanced practitioners oversee diagnostic evaluation and therapeutic planning. Nurses perform CBG testing, administer insulin, implement nurse-initiated hypoglycemia and hyperglycemia protocols, and provide bedside education. Pharmacists review medication regimens for agents that may cause hypoglycemia, including sulfonylurea-antimicrobial interactions, and optimize medication safety. Dietitians provide medical nutrition therapy and carbohydrate counting education. Diabetes care and education specialists deliver DSMES and serve as technology champions for CGM and insulin pump systems. Laboratory professionals ensure quality control of glucose and HbA1c testing. Behavioral health professionals address psychosocial barriers to self-management.[14][31] Structured interprofessional communication and shared decision-making are essential for cohesive care delivery, patient safety, and quality improvement. The care team should avoid therapeutic inertia—the failure to initiate or intensify therapy when treatment goals are not met—and prioritize timely modification of pharmacologic therapy, behavior-change interventions, technology use, and social or financial support systems. Social determinants of health, including food insecurity, housing instability, low health literacy, and financial constraints, should be routinely assessed and addressed, as these factors directly affect glycemic control and the patient’s ability to perform self-monitoring.

Structured interprofessional communication and shared decision-making are essential for cohesive care delivery, patient safety, and quality improvement. The care team should avoid therapeutic inertia—the failure to initiate or intensify therapy when treatment goals are not met—and prioritize timely modification of pharmacologic therapy, behavior-change interventions, technology use, and social or financial support systems. Social determinants of health, including food insecurity, housing instability, low health literacy, and financial constraints, should be routinely assessed and addressed, as these factors directly affect glycemic control and the patient’s ability to perform self-monitoring. Insulin is one of the most common medications associated with adverse events in hospitalized patients. Therefore, standardized insulin safety protocols, including nurse-initiated treatment algorithms for hypoglycemia prevention and management, are critical. In the context of BGM specifically, the team must ensure coordinated interpretation of glucose data, whether from CBG testing, CGM trend reports, or laboratory HbA1c results, and incorporate these findings into a unified care plan that is communicated across all team members during transitions of care, shift handoffs, and outpatient follow-up.[30][31][32] Central to all interprofessional efforts is patient engagement as an active and informed partnership. A communication style that uses person-centered, culturally sensitive, and strength-based language; elicits individual preferences and beliefs; and assesses literacy, numeracy, and potential barriers to care is recommended to optimize health outcomes and health-related quality of life. DSMES should be provided at diagnosis, annually, when complicating factors arise, and during transitions of care. DSMES has been shown to improve self-management behaviors, patient satisfaction, and glycemic outcomes. Health systems should adopt a culture of continuous quality improvement, implement benchmarking programs, and engage interprofessional teams to support sustainable improvements in care processes and health outcomes. Quality improvement methods have been documented to improve diabetes technology uptake, increase screening for psychosocial needs, and reduce inequities in access to diabetes care.[14][30][33]